Fulgent Genetics (FLGT) Cost of Revenue (2015 - 2026)

Fulgent Genetics has reported Cost of Revenue for 12 years, with the latest figure at $59.7 million in Q2 2026.

• Quarterly Cost of Revenue rose 26.06% year-over-year to $59.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $208.7 million (up 14.77% YoY) and the FY2025 annual result came in at $191.8 million, up 8.82% from the prior year.
• Cost of Revenue grew to $59.7 million in Q2 2026 per FLGT's latest filing, from $49.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $77.7 million in Q1 2022 and troughed at $42.4 million in Q1 2024.
• A 5-year average of $50.8 million and a median of $47.4 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 67.51% in 2022, then tumbled 39.07% in 2023.
• Over 5 years, Cost of Revenue stood at $54.7 million in 2022, then fell by 17.25% to $45.3 million in 2023, then fell by 2.01% to $44.4 million in 2024, then grew by 14.4% to $50.8 million in 2025, then advanced by 17.65% to $59.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $59.7 million, $49.6 million, and $50.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.